Clinical Trial Update: Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a three-drug combination of neratinib, fulvestrant, and eribulin for HR+/HER2+ advanced breast cancer. The study status is not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• Halaven (eribulin)
• Nerlynx (neratinib)

Snippet

Sponsor: Xijing Hospital | Conditions: Brest Cancer | Phase 2 | Status: NOT_YET_RECRUITING